eMedicine Specialties > Nephrology > Glomerular Diseases
Glomerulonephritis, Crescentic: Multimedia
Updated: Sep 25, 2008
Multimedia
 | Media file 1: Glomerulonephritis, crescentic. Light microscopy (25x hematoxylin and eosin stain): Compression of the glomerular tuft with a circumferential cellular crescent that occupies most of the Bowman space. Image courtesy of Madeleine Moussa, MD, FRCPC, Department of Pathology, London Health Sciences Centre, London, Ontario, Canada. |
 | Media file 2: Glomerulonephritis, crescentic. Light microscopy (200x hematoxylin and eosin stain): The normal renal architecture is lost. The glomerulus (*) is solid and hypercellular and surrounded by severe interstitial inflammatory infiltrate. Image courtesy of Suzanne Meleg-Smith, MD, Department of Pathology, Tulane University School of Medicine, New Orleans. |
 | Media file 3: Glomerulonephritis, crescentic. Light microscopy (200x periodic acid-Schiff stain): Bowman capsule (arrow) surrounds each glomerulus. The glomerular tuft (*) is distorted by a proliferation of epithelial cells (crescent), which replaces the urinary space. Image courtesy of Suzanne Meleg-Smith, MD, Department of Pathology, Tulane University School of Medicine, New Orleans. |
 | Media file 4: Glomerulonephritis, crescentic. Light microscopy (400x trichrome stain): The remnant of the glomerular tuft (*) is surrounded by the cellular crescent with abundant fibrin–red on trichrome stain. Interstitial edema separates the tubules, and scarce inflammatory cells are present. Image courtesy of Suzanne Meleg-Smith, MD, Department of Pathology, Tulane University School of Medicine, New Orleans. |
 | Media file 5: Glomerulonephritis, crescentic. Immunofluorescence (25x): Anti–glomerular basement membrane characterized by the presence of linear immunoglobulin G deposit along the glomerular basement membrane. Image courtesy of Madeleine Moussa, MD, FRCPC, Department of Pathology, London Health Sciences Centre, London, Ontario, Canada. |
More on Glomerulonephritis, Crescentic |
| Overview: Glomerulonephritis, Crescentic |
| Differential Diagnoses & Workup: Glomerulonephritis, Crescentic |
| Treatment & Medication: Glomerulonephritis, Crescentic |
| Follow-up: Glomerulonephritis, Crescentic |
 Multimedia: Glomerulonephritis, Crescentic |
| References |
| « Previous Page |
References
[Best Evidence] Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. Jul 2007;18(7):2180-8. [Medline].
Walsh M, Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int. Sep 2007;72(6):676-82. [Medline].
Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis. Sep 2008;67(9):1322-7. [Medline].
European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL. Clin Exp Immunol. Jul 1995;101 Suppl 1:29-34. [Medline].
de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol. Jul 2007;18(7):2189-97. [Medline].
Aoki S, Kotooka N, Yokoyama M, et al. Recurrence of rapidly progressive glomerulonephritis probably associated with two different kinds of drugs. Clin Nephrol. Sep 2000;54(3):249-51. [Medline].
Bachmeyer C, Cadranel JF, Demontis R. Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis. Nephrol Dial Transplant. Jun 2005;20(6):1274. [Medline].
Bombassei GJ, Kaplan AA. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). Am J Ind Med. 1992;21(2):141-53. [Medline].
Booth AD, Pusey CD, Jayne DR. Renal vasculitis--an update in 2004. Nephrol Dial Transplant. Aug 2004;19(8):1964-8. [Medline].
Cole E, Cattran D, Magil A, et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis. Sep 1992;20(3):261-9. [Medline].
Couser WG. Idiopathic rapidly progressive glomerulonephritis. Am J Nephrol. 1982;2(2):57-69. [Medline].
Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. Jan 27 2005;352(4):351-61. [Medline].
European Vasculitis Study Group. Clinical trial protocol: REMAIN. Randomised trial or prolonged remission-maintenance therapy in systemic vasculitis. June 2003.
Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol. Feb 1997;8(2):314-22. [Medline].
Flossmann O, Jones RB, Jayne DR, et al. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?. Ann Rheum Dis. Jul 2006;65(7):841-4. [Medline].
Garcia-Canton C, Toledo A, Palomar R, et al. Goodpasture's syndrome treated with mycophenolate mofetil. Nephrol Dial Transplant. Jun 2000;15(6):920-2. [Medline].
Goek ON, Stone JH. Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol. May 2005;17(3):257-64. [Medline].
Jarraya F, Abid M, Jlidi R, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with benzylthiouracil therapy: report of the first case. Nephrol Dial Transplant. Nov 2003;18(11):2421-3. [Medline].
Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. Jul 3 2003;349(1):36-44. [Medline].
Jayne DRW, Gaskin G, (EUVAS). Randomized trial of cyclophosphamide versus azathioprine during remission in ANCA-associated vasculitis (CYCAZAREM). J Am Soc Nephrol. 1999;10:105A.
Johnson JP, Moore J Jr, Austin HA 3rd, et al. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore). Jul 1985;64(4):219-27. [Medline].
Jordan SC. Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. J Clin Immunol. Nov 1995;15(6 Suppl):76S-85S. [Medline].
Kallenbach M, Duan H, Ring T. Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract. 2005;99(3):c92-6. [Medline].
Langford CA. How can relapses be detected and prevented in primary systemic small-vessel vasculitides?. Best Pract Res Clin Rheumatol. Apr 2005;19(2):307-20. [Medline].
Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med. Feb 15 1997;126(4):292-5. [Medline].
Murray AN, Cassidy MJ, Templecamp C. Rapidly progressive glomerulonephritis associated with rifampicin therapy for pulmonary tuberculosis. Nephron. 1987;46(4):373-6. [Medline].
Nowack R, Gobel U, Klooker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol. Sep 1999;10(9):1965-71. [Medline].
Ogata H, Kubo M, Tamaki K, et al. Crescentic glomerulonephritis due to rifampin treatment in a patient with pulmonary atypical mycobacteriosis. Nephron. 1998;78(3):319-22. [Medline].
Pagniez D, Fortin F, Delvallez L, et al. [Favorable course under cotrimoxazole of excavated pneumopathy complicating rapidly progressive glomerulonephritis: Wegener's granulomatosis?]. Rev Med Interne. Mar-Apr 1989;10(2):143-6. [Medline].
Stilmant MM, Bolton WK, Sturgill BC, et al. Crescentic glomerulonephritis without immune deposits: clinicopathologic features. Kidney Int. Feb 1979;15(2):184-95. [Medline].
Thompson CH, Kalowski S. Anti-glomerular basement membrane nephritis due to hydralazine. Nephron. 1991;58(2):238-9. [Medline].
Further Reading
Keywords
crescentic glomerulonephritis, idiopathic crescentic glomerulonephritis, idiopathic rapidly progressive glomerulonephritis, RPGN, GN, renal failure, kidney failure, acute nephritic syndrome, anti–glomerular basement membrane disease, anti-GBM disease, glomerulopathy, glomerular filtration rate, GFR, antineutrophil cytoplasmic antibody, ANCA, azotemia, oliguria, Goodpasture syndrome, Wegener granulomatosis, systemic lupus erythematosus, SLE, poststreptococcal glomerulonephritis, PSGN, membranoproliferative glomerulonephritis, MPGN
